Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387010 · ClinicalTrials.gov registry record · Phase 3
Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain
A Phase 3 study, sponsored by Cephalon.
- Terminated
- Registry status
- Phase 3
- Development phase
- 218
- Enrollment target
NCT00387010 is a Phase 3 study that was terminated before completion, run by Cephalon. The registered enrollment target is 218 participants.
The verdict
NCT00387010, a Phase 3 study, was terminated before completion, sponsored by Cephalon.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 218 participants
- Enrollment target
Study Summary
The primary purpose of the study is to evaluate the impact of treatment with fentanyl buccal tablets on the anxiety symptoms commonly associated with chronic pain in patients with breakthrough pain (BTP). Other purposes are to assess the management of BTP, to evaluate patient functioning, and to determine any influences on the successful dose achieved.
Interventions
- DRUG Fentanyl Buccal Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2006-12 |
| Est. Completion | 2007-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00387010
The ClinicalTrials.gov registry entry for NCT00387010 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fentanyl Buccal Tablets is the first listed.
NCT00387010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00387010 about?
NCT00387010 is a clinical study titled "Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain". The primary purpose of the study is to evaluate the impact of treatment with fentanyl buccal tablets on the anxiety symptoms commonly associated with chronic pain in patients with breakthrough pain (BTP). Other purposes are to assess the management of BTP, to evaluate patient functioning, and to det...
What is the current status of trial NCT00387010?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 218 participants. The study started on 2006-12. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00387010?
The interventions under investigation include: Fentanyl Buccal Tablets (DRUG).
Who is sponsoring clinical trial NCT00387010?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.